Postmarketing study investigating the safety and efficacy of recombinant human thrombomodulin treatment of disseminated intravascular coagulation (DIC) in neonatal patients

Trial Profile

Postmarketing study investigating the safety and efficacy of recombinant human thrombomodulin treatment of disseminated intravascular coagulation (DIC) in neonatal patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2016

At a glance

  • Drugs Thrombomodulin alfa (Primary)
  • Indications Disseminated intravascular coagulation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top